Tag: Andexxa

In clinical trials, major bleeding occurred in patients taking apixaban at a rate of approximately 2.1% to 4.5% per year. This raises a critical question for patients and clinicians: is there reversal for ELIQUIS® during emergencies? The answer is yes.

According to the International Society on Thrombosis and Haemostasis, the use of direct oral anticoagulants (DOACs) has increased significantly, driving the need for rapid and effective reversal strategies for life-threatening bleeding episodes. In this landscape, a significant development is the specific reversal agent for Factor Xa inhibitors, answering the question: what is the new anticoagulant reversal agent?.